Recent advances in drug action and therapeutics: Relevance of novel concepts in G‐protein‐coupled receptor and signal transduction pharmacology

• Published in: British journal of clinical pharmacology 2004-04, Vol.57 (4), p.373-387
• Main Authors: Brink, C. B., Harvey, B. H., Bodenstein, J., Venter, D. P., Oliver, D. W.
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cell Communication - physiology; drug action; Gap Junctions - physiology; GTP-Binding Proteins - physiology; G‐protein‐coupled receptors; Medical sciences; Miscellaneous; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmaceutical Preparations; Pharmacology. Drug treatments; Receptors, G-Protein-Coupled - agonists; Receptors, G-Protein-Coupled - physiology; Reviews; signal transduction; therapeutics
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/j.1365-2125.2003.02046.x

Problem statement During especially the past two decades many discoveries in biological sciences, and in particular at the molecular and genetic level, have greatly impacted on our knowledge and understanding of drug action and have helped to develop new drugs and therapeutic strategies. Furthermore, many exciting new drugs acting via novel pharmacological mechanisms are expected to be in clinical use in the not too distant future. Scope and contents of review In this educational review, these concepts are explained and their relevance illustrated by examples of drugs used commonly in the clinical setting, with special reference to the pharmacology of G‐protein‐coupled receptors. The review also addresses the basic theoretical concepts of full and partial agonism, neutral antagonism, inverse agonism and protean and ligand‐selective agonism, and the relevance of these concepts in current rational drug therapy. Moreover, the mechanisms whereby receptor signalling (and eventually response to drugs) is fine‐tuned, such as receptor promiscuity, agonist‐directed trafficking of receptor signalling, receptor trafficking, receptor ‘cross‐talk’ and regulators of G‐protein signalling (RGSs) are discussed, from theory to proposed therapeutic implications. Conclusions It is concluded that the understanding of molecular receptor and signal transduction pharmacology enables clinicians to improve their effective implementation of current and future pharmacotherapy, ultimately enhancing the quality of life of their patients.